FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March. TD Cowen's 46th Annual Health Care ConferenceFormat: Fireside ChatDate and Time: Monday, March 2, 2026 at 3:50 p.m. ET Location: Boston, MA Leerink Global Healthcare Conference Format: Fireside ChatDate and Time: Monday, M ...

Core Insights - Terns Pharmaceuticals has experienced a significant stock rally, raising expectations regarding its clinical pipeline and upcoming data [1][6] - The company is focused on developing therapies for liver and metabolic diseases, particularly targeting non-alcoholic steatohepatitis (NASH) and obesity [4][5] Company Overview - Terns Pharmaceuticals is a clinical-stage biotechnology company with a market capitalization of $4.29 billion and a net income of -$94.44 million [3] - The company's stock price has increased by 858.4% over the past year, significantly outperforming the S&P 500 [3] Clinical Pipeline - Key candidates in Terns' pipeline include TERN-101, TERN-201, TERN-501, and TERN-601, which are in various phases of clinical trials [5][8] - The company aims to address unmet medical needs in NASH and obesity through its focused pipeline of small-molecule candidates [4] Recent Transactions - ORBIMED Advisors LLC sold 5,409,671 shares of Terns Pharmaceuticals for approximately $125 million, reducing its position but still holding 2,153,300 shares [2][7] - Following the sale, Terns Pharmaceuticals represented 1.78% of ORBIMED's reportable assets under management [3] Market Expectations - The rapid appreciation in Terns' stock price reflects market anticipation of future success based on its clinical data [8] - Upcoming trial results will be critical in determining whether the current valuation is justified, particularly in terms of safety and differentiation from competitors [9]

First Turn Management, LLC disclosed a new position in Terns Pharmaceuticals (NASDAQ:TERN) in a February 13, 2026, SEC filing, acquiring 872,049 shares in an estimated $35.23 million trade. What happened According to an SEC filing dated February 13, 2026, First Turn Management, LLC initiated a new position in Terns Pharmaceuticals, acquiring 872,049 shares. At quarter’s end, the fund’s Terns Pharmaceuticals stake was valued at $35.23 million, reflecting the combined effect of new share acquisition and st ...

Core Viewpoint - Terns Pharmaceuticals, Inc. (TERN) shows potential for significant upside, with a mean price target of $58.13 indicating a 50.9% increase from its current price of $38.52 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets, with a standard deviation of $5.19, indicating variability among analysts [2] - The lowest estimate is $54.00, suggesting a 40.2% increase, while the highest estimate is $70.00, indicating an 81.7% potential surge [2] - Analysts' price targets should be approached with caution, as they may not always accurately reflect future stock movements [3][10] Earnings Estimates and Analyst Agreement - Analysts are optimistic about TERN's earnings prospects, with a consensus indicating better-than-previously estimated earnings [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 5.5% rise in the Zacks Consensus Estimate for the current year [12] - TERN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Implications of Price Target Clustering - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price direction [9] - While price targets can provide a starting point for further research, they should not be the sole basis for investment decisions [10][14]

Core Insights - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is recognized as one of the 11 best-performing stocks over the past 12 months [1] Group 1: Strategic Developments - Terns Pharmaceuticals has amended its Exclusive Option and License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd., converting a non-exclusive, royalty-free license into an exclusive, sublicensable, royalty-bearing, perpetual worldwide license for TERN-701, excluding the Hansoh Territory [2] - The company will pay a one-time upfront license fee of $1.0 million and tiered royalties of 0.75%-1.25% on annual net sales of TERN-701 products, with potential reductions applicable [3] Group 2: Analyst Sentiment - Citizens has raised its price target for Terns Pharmaceuticals from $35 to $57, maintaining an 'Outperform' rating, reflecting positive sentiment based on the interim Phase 1 CARDINAL ASH update showcasing TERN-701's strong profile and response rates [4] Group 3: Company Focus - Terns Pharmaceuticals specializes in developing small-molecule and combination therapies targeting NASH, oncology, and chronic liver disease, with clinical-stage programs focused on FXR, VAP-1, THR-β, and GLP-1 [5]

Core Insights - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is recognized as one of the top 14 stocks to buy currently, with a Buy rating and a price target of $56 from Truist Financial analyst Srikripa Devarakonda [1] - The stock's price target was raised from $35 to $56 following positive Phase 1 study results for TERN-701, aimed at treating chronic myeloid leukemia (CML) [2] - The study demonstrated a 64% major molecular response rate at 24 weeks, indicating strong efficacy and safety, which has led to a bullish outlook from analysts [3] Analyst Ratings - Mizuho Securities also maintains an Outperform rating on Terns Pharmaceuticals with a price target of $54, viewing TERN-701 as a potential best-in-disease treatment for CML [3] - The consensus among Wall Street analysts is a Strong Buy rating, with shares having increased over 300% in the last three months [4] - Analysts project an additional upside of 42.31%, based on a one-year average share price target of $53.75 [4] Company Overview - Terns Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious diseases, including cancer and obesity [5] - The company aims to initiate pivotal trials for TERN-701 by the end of 2026, as stated by CEO Amy Burroughs [4]

Group 1 - The article does not contain relevant content regarding company or industry insights [1]

Core Insights - Terns has had a successful year in 2025 and anticipates continued excitement in 2026, with the potential to become a best-in-disease therapy in the CML market [3] - The company has demonstrated unprecedented efficacy along with a strong safety and tolerability profile, positioning itself for the next generation of CML therapies [3] - Terns plans to engage with the FDA to discuss trial design and aims to initiate second-line and first-line trials promptly [4] Financial Position - Terns currently holds $1 billion in cash on its balance sheet, providing a strong financial foundation for upcoming trials and initiatives [4]

Summary of Terns Pharmaceuticals FY Conference Call Company Overview - **Company**: Terns Pharmaceuticals (NasdaqGS:TERN) - **Event**: FY Conference Call on January 12, 2026 - **Key Speakers**: Amy Burroughs (CEO), Emil Kuriakose (CMO), Scott Harris (CDO) [1] Industry Context - **Industry**: Chronic Myeloid Leukemia (CML) treatment - **Current Market Dynamics**: - CML was previously a fatal disease until the introduction of BCR-ABL inhibitors like Gleevec (Imatinib) in 2001 - Asiminib, an allosteric inhibitor, gained a 22% market share in the front-line treatment within three quarters of its approval in November 2024 [4][5] Core Points and Arguments - **Performance in 2025**: Terns had a successful year and anticipates continued success in 2026, aiming to establish itself as a leader in CML therapy [2] - **Financial Position**: Terns has $1 billion in cash, alleviating financing concerns until commercial launch [3] - **Efficacy of Terns 701**: - Terns 701 shows unprecedented efficacy with a 75% major molecular response (MMR) rate in a highly refractory patient population [6][9] - Deep molecular response (DMR) rate of 36% at recommended doses [7] - Comparison with Asiminib indicates Terns 701 may outperform in both efficacy and safety [10][20] - **Safety Profile**: - No dose-limiting toxicities observed; majority of adverse events were low-grade [9][11] - Terns 701 does not exhibit the pancreatic toxicity (20%) or hypertension (18%) seen with Asiminib [5][6] - Administered once daily without food restrictions, enhancing patient convenience [9][26] Market Opportunities - **Potential for Terns 701**: - Positioned as a next-generation therapy with better efficacy and safety compared to existing treatments [10][25] - Anticipated to capture significant market share in the front-line treatment of CML [25][26] - **Regulatory Pathway**: - Plans to engage with the FDA for trial design and dose selection in 2026 [22][29] - A second-line plus trial is expected to be initiated, with confidence in achieving MMR as a primary endpoint [22][23] Additional Insights - **Patient Population**: - High baseline disease burden among trial participants, with 64% showing lack of efficacy to previous treatments [12][13] - Notable patient cases demonstrate Terns 701's effectiveness in individuals resistant to Asiminib [18][19] - **Future Directions**: - Terns plans to open a mutation cohort for patients with specific mutations, enhancing the understanding of Terns 701's efficacy [21] - Additional data releases and longer-term safety studies are anticipated in 2026 [26][27] Conclusion - Terns Pharmaceuticals is positioned to make significant advancements in CML treatment with Terns 701, backed by strong efficacy and safety data, a solid financial foundation, and strategic regulatory plans for 2026 [27]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are significant, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned to profit from the surge in electricity demand driven by AI data centers [3][6] Market Position - The company is described as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend due to tariffs [5][6] - It has a unique footprint in nuclear energy, which is considered vital for America's future power strategy [7][14] Financial Health - The company is noted for being debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened by debt [8][10] - It also has a substantial equity stake in another AI-related company, providing indirect exposure to multiple growth engines without the associated premium costs [9][10] Market Sentiment - There is a growing interest from Wall Street in this company, as it is seen as undervalued and capable of delivering real cash flows while owning critical infrastructure [8][10] - The company is trading at less than 7 times earnings, making it an attractive investment opportunity in the context of AI and energy [10][11] Future Outlook - The influx of talent into the AI sector is expected to drive rapid advancements and innovation, reinforcing the notion that investing in AI is backing the future [12][13] - The combination of AI infrastructure needs, energy demands, and the onshoring boom presents a unique investment landscape that this company is well-positioned to navigate [14][15]